Compare iShares MSCI South Korea ETF (EWY) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Johnson & Johnson — how do they compare? iShares MSCI South Korea ETF trades at $165.37, while Johnson & Johnson trades at $249.71 (market cap $594.63B). The key difference: Johnson & Johnson pays a 2.17% dividend while iShares MSCI South Korea ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, iShares MSCI South Korea ETF nearer its low. Which is the better fit depends on your goals.
| EWY | JNJ | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $267.24 |
52-Week Low | $70.65 | $162.98 |
Market Cap | — | $594.63B |
Volume | — | 6,156,228 |
Enterprise Value | — | $627.57B |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY, the iShares MSCI South Korea ETF, is trading at $166.48, down 5.93% amid significant volatility in South Korean equities. Technical indicators show a bearish trend with strong selling pressure, while the underlying Kospi Index has experienced sharp declines from recent highs. The ETF remains heavily concentrated in Samsung and SK Hynix, making it highly sensitive to semiconductor and AI market dynamics.
The outlook remains challenging with ongoing volatility in chip stocks and foreign investor selling. While long-term AI demand provides potential upside, current market conditions suggest continued pressure. Key risks include single-stock concentration and global tech sector volatility, requiring careful risk management for investors.
Johnson & Johnson (JNJ) trades at $249.42, down 1.75% over 24 hours, with a bullish technical signal from moving averages but bearish oscillators. The company reported Q2 2026 EPS of $2.90, beating estimates, and raised full-year guidance. Revenue grew 6.6% annually, supported by strong pharmaceutical sales. Analyst consensus is bullish with a $281 price target, and the stock offers a stable dividend with recent payouts of $1.34 per share.
Outlook remains positive due to robust fundamentals, innovation in medtech and pharmaceuticals, and dividend king status. Risks include patent expirations, regulatory pressures, and macroeconomic volatility. The current valuation at P/E 28.66 may limit near-term upside, but long-term growth prospects appear solid.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
